Newsroom
Sorted by: Latest
-
Kopin Secures Multiple Orders for Sentinel FPV™ Prototypes as Drone Dominance Program Accelerates
WESTBOROUGH, Mass.--(BUSINESS WIRE)--Kopin Secures Multiple Orders for Sentinel FPV™ Prototypes as Drone Dominance Program Accelerates...
-
ESS Added to Russell Microcap® Index
WILSONVILLE, Ore.--(BUSINESS WIRE)--ESS Added to Russell Microcap® Index...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Innovative Aerosystems to Join U.S. Small-Cap Russell 2000® Index
EXTON, Pa.--(BUSINESS WIRE)--Innovative Solutions & Support, Inc. (Nasdaq: ISSC) dba Innovative Aerosystems and its subsidiaries (“IA” or the "Company"), a leading provider of advanced avionic solutions for commercial, business, and military aviation markets, today announced that the Company was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 29, as part of the 2026 Russell indexes reconstitution. "We are pleased to be joining these imp...
-
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU).The Phas...
-
Valmark Financial Group Named a 2026 Top Workplace for Seventh Consecutive Year, Reflecting a Culture Built to Last
AKRON, Ohio--(BUSINESS WIRE)--Valmark Financial Group has been named a 2026 Top Workplace by Cleveland.com and The Plain Dealer, marking its seventh consecutive year receiving the honor and underscoring the strength of a culture that continues to attract, develop, and retain exceptional talent. The award is based entirely on employee feedback gathered through an independent third-party survey measuring workplace culture, leadership, employee engagement, professional growth, communication, and o...
-
RXO Wins Prestigious “Best in Cargo Security” Award from CargoNet
CHARLOTTE, N.C.--(BUSINESS WIRE)--RXO (NYSE: RXO), a leading provider of asset-light transportation solutions, has been awarded Verisk CargoNet’s "Best in Cargo Security" Award. This honor recognizes RXO’s industry-leading commitment to cargo theft prevention, fraud detection, and the sharing of critical crime intelligence to strengthen the national supply chain. CargoNet, a Verisk business, serves as a national information-sharing system that connects transportation companies, shippers, and la...
-
Crane Company Announces Date for Second Quarter 2026 Earnings Release and Teleconference
STAMFORD, Conn.--(BUSINESS WIRE)--Crane Company (NYSE: CR) announces the following schedule and teleconference information for its second quarter 2026 earnings release: Earnings Release: July 28, 2026 after close of market by public distribution and the Crane Company website at www.craneco.com. Teleconference: July 29, 2026 at 10:00 AM (Eastern) hosted by Alex Alcala, President & CEO, and Richard A. Maue, Executive Vice President & CFO. The call can be accessed in a listen-only mode via...
-
HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. Sickle cell disease and beta thalassemia are inherited blood disorders that can cause serious, lifelong complications b...
-
Causeway Capital Management LLC UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Causeway Capital Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must b...